NLRP3 and Parkinson disease: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of PD showed stimulation of NLRP3 and a loss of dopaminergic neurons followed by motor deficit, whereas a lack of NLRP3 in MPTP-treated mice showed reduced neurodegeneration and inhibition of cytokine production [54].